Cubist Pharmaceuticals reports $560.3 million in 2009 revenue, meets Wall Street forecast

Cubist reports $560.3 million in 2009 revenue

LEXINGTON, Mass. — Cubist Pharmaceuticals Inc. said Monday it posted $560.3 million in revenue during 2009, up 30 percent from a year earlier and meeting Wall Street forecasts.

The company said U.S. sales of the antibiotic Cubicin, its only marketed product, rose 26 percent to $524 million. It also had $13.8 million in revenue from international sales and $22.5 million in service revenue.

Analysts polled by Thomson Reuters expected revenue of $559.5 million, on average.

Revenue in 2008 totaled $433.6 million.

Fourth-quarter U.S. Cubicin sales rose 23 percent to $147.8 million.

The company said it will release full fourth-quarter and 2009 financial results on Jan. 21.

Shares of Cubist rose 12 cents to $18.90 in morning trading.